Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second-line chemotherapy

被引：0

作者：

Nather, A ^{[1
]}

Mayerhofer, K ^{[1
]}

Grimm, C ^{[1
]}

Hefler, L ^{[1
]}

Leodolter, S ^{[1
]}

Obermair, A ^{[1
]}

Joura, EA ^{[1
]}

机构：

[1] Univ Vienna, Dept Gynecol & Obstet, Sch Med, A-1090 Vienna, Austria

来源：

ANTICANCER RESEARCH | 2003年 / 23卷 / 3C期

关键词：

ovarian cancer; anaemia; thrombocytosis; second-line chemotherapy; prognostic factors;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: To investigate the incidence and the prognostic value of platelet count and serum haemoglobin (Hb) in patients with recurrent ovarian cancer prior to second-line chemotherapy. Materials and Methods: Clinical records were reviewed for 31 patients with recurrent ovarian cancer. Survival analysis was evaluated by univariate (Kaplan-Meier product limit method and log-rank test) analysis. We analysed the results for the overall survival.. Anaemia and thrombocytosis were defined as a serum Hb level <12g/dl and as platelet count >300.000/muL, respectively. Results: Thrombocytosis and tumour anaemia were present in 55% and 42% of the patients, respectively. Tumour anaemia was of no prognostic value with respect to overall survival in our series. In patients with thrombocytosis, the median survival rate was reduced (p=0.05). Conclusion: Our data suggest that a platelet count >300,000/muL appears to be an adverse prognostic parameter in patients with recurrent ovarian cancer prior to a second-line chemotherapy.

引用

页码：2991 / 2994

页数：4

共 50 条

[1] Second-line chemotherapy for ovarian cancer
Chan, S
LANCET ONCOLOGY, 2003, 4 (06): : 333 - 334
[2] Ovarian cancer - Second-line chemotherapy: What are the options?
Gore, ME
EUROPEAN JOURNAL OF CANCER, 1999, 35 : S311 - S311
[3] Timing for starting second-line therapy in recurrent ovarian cancer
Guarneri, Valentina
Barbieri, Elena
Dieci, Maria Vittoria
Piacentini, Federico
Conte, PierFranco
EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (01) : 49 - 55
[4] Second-line treatment of first relapse recurrent ovarian cancer
Chua, Terence C.
Liauw, Winston
Robertson, Gregory
Morris, David L.
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2010, 50 (05): : 465 - 471
[5] The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer
Giuliani, Jacopo
Bonetti, Andrea
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (09) : 1872 - 1876
[6] Second-line chemotherapy for metastatic/recurrent head and neck cancer
Ferrari, D.
Codeca, C.
Caldiera, S.
Zonato, S.
Luciani, A.
Fiore, J.
Cossu-Rocca, M.
Verri, E.
Foa, P.
ANNALS OF ONCOLOGY, 2007, 18 : 56 - 56
[7] The role of topotecan as second-line therapy in patients with recurrent ovarian cancer
Beshara, N
Fung, MFK
Faught, W
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2002, 23 (04) : 287 - 290
[8] Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer
Hironaka S.
Zenda S.
Boku N.
Fukutomi A.
Yoshino T.
Onozawa Y.
Gastric Cancer, 2006, 9 (1) : 14 - 18
[9] Second-line chemotherapy for gallbladder cancer
Wongjarupong, Nicha
Hassan, Mohamed Abdelrahim Muddathir
Sanhueza, Cristobal T.
Hartgers, Mindy L.
Hassan, Fatima
Roberts, Lewis R.
Mahipal, Amit
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[10] Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9)
Esposito, Francesca
Cecere, Sabrina Chiara
Magazzino, Francescapaola
Katsaros, Dionyssios
Ottaiano, Alessandro
Gadducci, Angiolo
Pisano, Carmela
Scalone, Sinnona
Rabaiotti, Emanuela
Salutari, Vanda
Cormio, Gennaro
Canuto, Emilie Marion
Greggi, Stefano
Savarese, Antonella
Marinaccio, Marco
Scollo, Paolo
Santeufemia, Davide Adriano
Sacco, Cosimo
Facchini, Gaetano
Pignata, Sandro
ONCOLOGY, 2014, 86 (5-6) : 351 - 358

← 1 2 3 4 5 →